Targeted Therapies Forum 2022, Breakout Session: Dr. Angel Qin discusses the use of Patritumab Deruxtecan for EGFR+ NSCLC.
We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech
For more, please visit http://cancerGRACE.org/.
To join the conversation, visit https://cancergrace.org/forum.